First human trial launches for aggressive bile duct cancer treatment
NCT ID NCT07107750
Summary
This early-stage trial is testing whether adding a new drug called emavusertib to standard chemotherapy and immunotherapy helps people with advanced bile duct cancer. Researchers will enroll 48 adults who haven't received prior treatment for their advanced cancer to find the safest dose and see if the combination can control the disease. After initial treatment, patients continue taking emavusertib and immunotherapy as maintenance therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BILIARY TRACT CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.